Bernstein Analysts See Strategic Discipline Ahead Under New UnitedHealth CEO

With a price target of $377, analysts from the Bernstein SocGen Group reiterated their Outperform rating on UnitedHealth Group Incorporated (NYSE:UNH) on June 4. The analysts outlined the company’s underwriting culture, management team composition, and strategy choices as top considerations for Steve Hemsley, the recently appointed CEO.

Bernstein Analysts See Strategic Discipline Ahead Under New UnitedHealth CEO

Ken Wolter/Shutterstock.com

Bernstein analysts took note of a change in the company’s underwriting culture while highlighting their expectations for the new CEO’s responsibilities. They expect 2026 to be an important year for pricing restraint, with a focus on maintaining margins rather than expanding.

Steve Hemsley, UnitedHealth’s new CEO, has stated that he will immediately concentrate on pricing discipline. This includes predicting financial and care-related behaviors, such as commercial pricing and Medicare Advantage bids. Moreover, Bernstein’s analysts brought up the possibility of a significant strategic choice involving a possible division of UnitedHealth’s UHC and Optum operations.

UnitedHealth Group Incorporated (NYSE:UNH) is a renowned US multinational corporation that provides managed healthcare and insurance services. The company operates through four main segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx.

While we acknowledge the potential of UNH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than UNH and that has 100x upside potential, check out our report about the cheapest AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.